IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Aristo Bio-Tech and Lifescience IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Vadodara and caters to Chemical - Pesticides sector. Beeline Capital Advisors Private is the merchant banker of Aristo Bio-Tech and Lifescience IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 12th April 2022.
Aristo Bio-Tech and Lifescience IPO posted revenues of Rs 258.14 crores and PAT of Rs 5.18 crores in FY23 on annualised basis.Financial results of Aristo Bio-Tech and Lifescience IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Aristo Bio-Tech and Lifescience IPO PAT Margin is [●]%, ROCE (Return on Capital Employed) is 10.00% as per latest financial. The below table shows Aristo Bio-Tech and Lifescience IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Aristo Bio-Tech and Lifescience IPO is Rs 49.02 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Aristo Bio-Tech and Lifescience IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Aristo Bio-Tech and Lifescience IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Aristo Bio-Tech and Lifescience IPO is ₹49.02 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Aristo Bio-Tech and Lifescience IPO has a Price-to-Earnings (PE) ratio of 9.46 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Aristo Bio-Tech and Lifescience IPO reported revenue of ₹258.14 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Aristo Bio-Tech and Lifescience IPO provide insights into sales growth, market demand, and business scalability.
Aristo Bio-Tech and Lifescience recorded an EBITDA of ₹ 10.18 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Aristo Bio-Tech and Lifescience Profit After Tax (PAT) is ₹0.00 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 303.12 Cr.
EBITDA Margin:
3.36
%
Net Worth: ₹ 17.42 Cr.
Market Capitalisation:
₹ 49.02 Cr.
P/E:
9.46 times
P/BV: 1.61 times
EV/EBITDA: 7.57 times
Aristo Bio-Tech and Lifescience operates in Chemical - Pesticides and Manufacturing Of Pesticides. The Issue is listed on NSE EMERGE in Jan, 2023. Aristo Bio-Tech and Lifescience IPO size was 13.05 with Issue price of 72.00 .
Merchant Banker(s) of Aristo Bio-Tech and Lifescience IPO: Beeline Capital Advisors Private Limited
Aristo Bio-Tech and Lifescience IPO subscription was 217.72 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Aristo Bio-Tech and Lifescience IPO listed at a listing price of 80.00 against the offer price of 72.00.
The current market price of Aristo Bio-Tech and Lifescience is 133.60.
Why Us?
